Guardicine solves a major gap in stroke treatment in which time is brain & life. In fact, there are treatments if acted early. The first line drug, tPA, can reverse the damage & reduce disability & mortality for most strokes. However, it must be injected to the patient within 4.5 hrs. Unfortunately, >90% of patients are late for the drug due to sleep or misjudgment. Other treatment also has similar time limit. Guardicine's proprietary device can auto detect the start of a stroke and alert the patient to a hospital in time for critical early treatment.
Currently there are 6.6 (80) million of stroke survivors in US (world), plus additional 0.78M (15) of strokes in US (world) each year. Stroke is a highly recurring disease. Our initial target is those highly motivated patients with stroke history and in great risk and fear of another stroke. The market size just for the group is about $1 billion in US and $10B in the world according to survey. No similar product on market now.